Physicochemical Properties
| Molecular Formula | C3H7O6PNA2.XH2O |
| Molecular Weight | 216.0374 |
| Exact Mass | 233.988 |
| CAS # | 154804-51-0 |
| PubChem CID | 22251426 |
| Appearance | White to off-white solid powder |
| Melting Point | 102～104 ℃ |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 3 |
| Heavy Atom Count | 13 |
| Complexity | 117 |
| Defined Atom Stereocenter Count | 0 |
| InChi Key | OFNNKPAERNWEDD-UHFFFAOYSA-L |
| InChi Code | InChI=1S/C3H9O6P.2Na.H2O/c4-1-3(5)2-9-10(6,7)8;;;/h3-5H,1-2H2,(H2,6,7,8);;;1H2/q;2*+1;/p-2 |
| Chemical Name | disodium;2,3-dihydroxypropyl phosphate;hydrate |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion Peak serum phosphate concentration is reached in 4h. Inorganic phosphate produced is eliminated in the urine. There may be a very small amount of glycerophosphate excreted in the urine unchanged. Metabolism / Metabolites Glycerophosphate is hydrolyzed to form inorganic phosphate. The extent of this reaction is dependent on serum alkaline phosphatase activity. Biological Half-Life Inorganic phosphate has a half-life of elimination of 2.06h. |
| References |
[1]. Inhibition of the nucleotidase effect of alkaline phosphatase by beta-glycerophosphate. Nature. 1968 Jul 6;219(5149):73-5. [2]. Beta-glycerophosphate accelerates calcification in cultured bovine vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1995 Nov;15(11):2003-9. [3]. Effects of dexamethasone, ascorbic acid and β-glycerophosphate on the osteogenic differentiation of stem cells in vitro. Stem Cell Res Ther. 2013;4(5):117. |
| Additional Infomation |
Sodium glycerophosphate is one of several glycerophosphate salts. It is used clinically to treat or prevent low phosphate levels. Glycerophosphate is hydrolyzed to inorganic phosphate and glycerol in the body. The extent of this reaction is dependent on the activity of serum alkaline phosphatases. Sodium Glycerophosphate is the sodium salt form of an organic phosphate compound that provides phosphate for nutritional purposes. In addition, sodium glycerophosphate can be used as a phosphate diluting agent upon internal contamination with the beta-emiting radioisotope phosphate P 32 (P-32) that competes with P-32 for absorption. As sodium glycerophosphate is administered in high amounts, the absorption of P-32 is prevented or minimalized. See also: sodium glycerophosphate anhydrous (annotation moved to). Drug Indication Sodium glycerophosphate is indicated for use as a source of phosphate in total parenteral nutrition. It is used in combination with amino acids, dextrose, lipid emulsions, and other electrolytes. FDA Label Mechanism of Action Sodium glycerophosphate acts as a donor of inorganic phosphate. See [DB09413] for a description of phosphate's role in the body. Pharmacodynamics Glycerophosphate acts as a source of inorganic phosphate through hydrolysis. |
Solubility Data
| Solubility (In Vitro) | H2O: 250 mg/mL |
| Solubility (In Vivo) |
Solubility in Formulation 1: 25 mg/mL (Infinity mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with heating and sonication. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.6288 mL | 23.1439 mL | 46.2877 mL | |
| 5 mM | 0.9258 mL | 4.6288 mL | 9.2575 mL | |
| 10 mM | 0.4629 mL | 2.3144 mL | 4.6288 mL |